- Home
- VNDA vs PEPG Comparison
VNDA vs PEPG Comparison
Compare VNDA & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- PEPG
- Stock Information
- Founded
- VNDA 2002
- PEPG 2018
- Country
- VNDA United States
- PEPG United States
- Employees
- VNDA N/A
- PEPG N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- VNDA Health Care
- PEPG Health Care
- Exchange
- VNDA Nasdaq
- PEPG Nasdaq
- Market Cap
- VNDA 270.2M
- PEPG 250.3M
- IPO Year
- VNDA 2006
- PEPG 2022
- Fundamental
- Price
- VNDA $4.94
- PEPG $4.32
- Analyst Decision
- VNDA Strong Buy
- PEPG Buy
- Analyst Count
- VNDA 2
- PEPG 3
- Target Price
- VNDA $15.50
- PEPG $14.67
- AVG Volume (30 Days)
- VNDA 643.5K
- PEPG 133.3K
- Earning Date
- VNDA 11-06-2024
- PEPG 11-07-2024
- Dividend Yield
- VNDA N/A
- PEPG N/A
- EPS Growth
- VNDA N/A
- PEPG N/A
- EPS
- VNDA N/A
- PEPG N/A
- Revenue
- VNDA $190,858,000.00
- PEPG N/A
- Revenue This Year
- VNDA $5.13
- PEPG N/A
- Revenue Next Year
- VNDA $42.65
- PEPG N/A
- P/E Ratio
- VNDA N/A
- PEPG N/A
- Revenue Growth
- VNDA N/A
- PEPG N/A
- 52 Week Low
- VNDA $3.46
- PEPG $4.00
- 52 Week High
- VNDA $6.75
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- VNDA 50.36
- PEPG 23.52
- Support Level
- VNDA $4.82
- PEPG $4.00
- Resistance Level
- VNDA $5.55
- PEPG $4.77
- Average True Range (ATR)
- VNDA 0.22
- PEPG 0.56
- MACD
- VNDA -0.02
- PEPG -0.05
- Stochastic Oscillator
- VNDA 32.22
- PEPG 9.14
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.